CMMB NASDAQ
Chemomab Therapeutics Ltd.
1W: -33.8%
1M: -47.6%
3M: -40.4%
YTD: -20.1%
1Y: -45.8%
3Y: -60.7%
5Y: -97.0%
$1.43
+0.13 (+10.00%)
Weekly Expected Move ±20.2%
$1
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$8.8M
52W Range1.05-3.58
Volume40,837
Avg Volume143,320
Beta0.66
Dividend—
Analyst Ratings
Company Info
CEOAdi Mor George
Employees12
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-12
Websitechemomab.com
Building C
Tel Aviv-Yafo, TA 6158101
IL
Tel Aviv-Yafo, TA 6158101
IL
972 77 331 0156
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Latest News
Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 9.2% – Still a Buy?
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Chemomab to merge with Scipher Medicine
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cohen Neil Harris | S-Sale | 1,000 | $2.80 | 2026-08-28 |
| Cohen Neil Harris | S-Sale | 1,304 | $2.85 | 2026-08-27 |
| Melincoff Gwen A | 8,621 | $1.86 | 2026-06-01 | |
| Mor George Adi | P-Purchase | 4,878 | $2.05 | 2026-05-29 |
| Mor George Adi | P-Purchase | 4,926 | $2.08 | 2026-05-29 |